Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 464 participants.

Also called NCT02036515

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 464 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02036515
  • EudraCT 2013-003697-26
Other papers using this trial's data
  • Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study Diabetes, obesity & metabolism, 2018-03 DOI, PubMed 28921862, PMC5836931 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02036515. Randomized; double masking; primary purpose treatment. Start 2014-03-12 (actual); primary completion 2016-06-06 (actual). Results posted on 2017-07-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ertugliflozin 5 mg
Intervention (Drug)
Ertugliflozin 15 mg
Intervention (Drug)
Placebo for ertugliflozin 5 mg
Intervention (Drug)
Metformin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Glimepiride
Intervention (Biological)
Insulin
Intervention (Drug)
Placebo for ertugliflozin 10 mg
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02036515
Content hash
380af673238c1d0bae14410b1667d539b585e01dde2fc5a812358ca241a591b7